Lumakras and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Lumakras (sotorasib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Lumakras. It is created by eHealthMe based on reports of 1,895 people who have side effects when taking Lumakras from the FDA, and is updated regularly.

What is Lumakras?

Lumakras has active ingredients of sotorasib. eHealthMe is studying from 1,895 Lumakras users. Check the latest studies of Lumakras.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,510 drugs and 1,635 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

On Jul, 31, 2026

1,895 people reported to have side effects when taking Lumakras.
Among them, 11 people (0.58%) have Malignant neoplasm progression.

Could Lumakras cause Malignant neoplasm progression?

Among these 11 people:

How long have people been on Lumakras when they have Malignant neoplasm progression? *

What is the gender of people who have Malignant neoplasm progression when taking Lumakras? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Malignant neoplasm progression when taking Lumakras? *

What are other drugs people take besides Lumakras? *

Krazati: 1 person, 9.09%
Keytruda: 1 person, 9.09%
Dexamethasone: 1 person, 9.09%

What are other side effects people have besides Malignant neoplasm progression? *

Swallowing Difficulty: 2 people, 18.18%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 18.18%
Pneumonia: 1 person, 9.09%
Muscle Aches (muscle pain): 1 person, 9.09%
Injury: 1 person, 9.09%
Hepatic Enzyme Increased: 1 person, 9.09%
Fatigue (feeling of tiredness): 1 person, 9.09%
Drug Ineffective: 1 person, 9.09%
Diarrhea: 1 person, 9.09%
Diabetes: 1 person, 9.09%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 27.27%
Neoplasm Malignant (cancer tumour): 2 people, 18.18%
K-Ras Gene Mutation: 2 people, 18.18%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lumakras and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lumakras:

Lumakras (1,895 reports)

Browse all side effects of Lumakras:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,510 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,635 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sotorasib (the active ingredients of Lumakras) and Lumakras (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.